These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 22020739

  • 1. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
    Mullins CD, Hsiao FY, Onukwugha E, Pandya NB, Hanna N.
    Cancer; 2012 Jun 15; 118(12):3173-81. PubMed ID: 22020739
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S, Bridgewater J.
    Cancer; 2007 Mar 15; 109(6):1082-9. PubMed ID: 17265519
    [Abstract] [Full Text] [Related]

  • 3. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.
    Health Technol Assess; 2008 May 15; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [Abstract] [Full Text] [Related]

  • 4. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
    Wade R, Duarte A, Simmonds M, Rodriguez-Lopez R, Duffy S, Woolacott N, Spackman E.
    Pharmacoeconomics; 2015 May 15; 33(5):457-66. PubMed ID: 25616671
    [Abstract] [Full Text] [Related]

  • 5. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study.
    Koperna T, Semmler D.
    Hepatogastroenterology; 2003 May 15; 50(54):1903-9. PubMed ID: 14696430
    [Abstract] [Full Text] [Related]

  • 6. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
    Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P.
    Health Technol Assess; 2006 Nov 15; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial.
    Shiroiwa T, Takeuchi T, Fukuda T, Shimozuma K, Ohashi Y.
    Value Health; 2012 Nov 15; 15(2):255-60. PubMed ID: 22433756
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
    Hillner BE, Schrag D, Sargent DJ, Fuchs CS, Goldberg RM.
    Cancer; 2005 Nov 01; 104(9):1871-84. PubMed ID: 16177989
    [Abstract] [Full Text] [Related]

  • 9. Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer.
    Lairson DR, Parikh RC, Cormier JN, Chan W, Du XL.
    Pharmacoeconomics; 2014 Oct 01; 32(10):1005-13. PubMed ID: 24920195
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
    Zhou J, Zhao R, Wen F, Zhang P, Wu Y, Tang R, Chen H, Zhang J, Li Q.
    Tumori; 2016 Jun 02; 2016(3):294-300. PubMed ID: 27056335
    [Abstract] [Full Text] [Related]

  • 11. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
    Kashiwa M, Matsushita R.
    Clin Ther; 2020 Jul 02; 42(7):1361-1375. PubMed ID: 32616433
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
    Wen F, Yao K, Du ZD, He XF, Zhang PF, Tang RL, Li Q.
    World J Gastroenterol; 2014 Dec 21; 20(47):17976-84. PubMed ID: 25548497
    [Abstract] [Full Text] [Related]

  • 13. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
    Tikhonova IA, Huxley N, Snowsill T, Crathorne L, Varley-Campbell J, Napier M, Hoyle M.
    Pharmacoeconomics; 2018 Jul 21; 36(7):837-851. PubMed ID: 29498000
    [Abstract] [Full Text] [Related]

  • 14. Cost-Effectiveness of Treatment Sequences of Chemotherapies and Targeted Biologics for Elderly Metastatic Colorectal Cancer Patients.
    Parikh RC, Du XL, Robert MO, Lairson DR.
    J Manag Care Spec Pharm; 2017 Jan 21; 23(1):64-73. PubMed ID: 28025930
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Graham CN, Hechmati G, Hjelmgren J, de Liège F, Lanier J, Knox H, Barber B.
    Eur J Cancer; 2014 Nov 21; 50(16):2791-801. PubMed ID: 25219451
    [Abstract] [Full Text] [Related]

  • 16. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
    Hsiao FY, Mullins CD, Onukwugha E, Pandya N, Hanna N.
    J Am Geriatr Soc; 2011 Sep 21; 59(9):1717-23. PubMed ID: 21831168
    [Abstract] [Full Text] [Related]

  • 17. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
    Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts S.
    J Clin Oncol; 2006 Jul 20; 24(21):3347-53. PubMed ID: 16849748
    [Abstract] [Full Text] [Related]

  • 18. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Fleeman N, Abdulla A, Bagust A, Beale S, Richardson M, Stainthorpe A, Boland A, Kotas E, McEntee J, Palmer D.
    Pharmacoeconomics; 2018 Mar 20; 36(3):289-299. PubMed ID: 29178025
    [Abstract] [Full Text] [Related]

  • 19. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
    Hsu TC, Chen HH, Yang MC, Wang HM, Chuang JH, Jao SW, Chiang HC, Wen CY, Tseng JH, Chen LT.
    Value Health; 2011 Mar 20; 14(5):647-51. PubMed ID: 21839401
    [Abstract] [Full Text] [Related]

  • 20. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
    Kim JY, Kim YJ, Lee KW, Lee JS, Kim DW, Kang SB, Lee HS, Jang NY, Kim JS, Kim JH.
    Jpn J Clin Oncol; 2013 Feb 20; 43(2):132-8. PubMed ID: 23204187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.